![Anna Berkenblit](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anna Berkenblit
Director/Board Member at
SURROZEN, INC.
Net worth: 61 358 $ as of 2026-05-30
Profile
Anna Berkenblit currently serves as Director at Surrozen Operating, Inc. since 2019, Independent Director at Surrozen, Inc. since 2018, Director at Nested Therapeutics, Inc., and Chief Scientific & Medical Officer at Pancreatic Cancer Action Network, Inc. Former roles include Chief Medical Officer & Senior Vice President at ImmunoGen, Inc. from 2019 to 2023, Vice President at Pfizer Inc. from 2007 to 2011, Vice President & Head-Clinical Research at AVEO Pharmaceuticals, Inc. from 2011 to 2013, and Senior Vice President-Clinical Development at H3 Biomedicine, Inc. from 2013 to 2015.
Education includes graduate degrees from Harvard University and Massachusetts Institute of Technology, an undergraduate degree from Yale University, and a doctorate from Harvard Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SURROZEN INC 0.02% | 2026-05-12 | 2,341 ( 0.02% ) | 61 358 $ | 2026-05-30 |
Anna Berkenblit active positions
| Companies | Position | Start |
|---|---|---|
| SURROZEN, INC. | Director/Board Member | 2018-07-31 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Director/Board Member | 2019-03-13 |
Nested Therapeutics, Inc.
 Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a drug discovery biotechnology company | Director/Board Member | - |
Pancreatic Cancer Action Network, Inc.
 Pancreatic Cancer Action Network, Inc. Medical/Nursing ServicesHealth Services Operates a charity which focuses on the early diagnosis of pancreatic cancer | Chief Tech/Sci/R&D Officer | - |
Former positions of Anna Berkenblit
| Companies | Position | End |
|---|---|---|
| IMMUNOGEN, INC. | Chief Tech/Sci/R&D Officer | 2023-08-30 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of genomic drugs | Corporate Officer/Principal | 2014-12-31 |
| AVEO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2012-12-31 |
| PFIZER INC. | Corporate Officer/Principal | 2011-08-31 |
Training of Anna Berkenblit
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
67
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops cancer therapeutics | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pancreatic Cancer Action Network, Inc.
Pancreatic Cancer Action Network, Inc. Medical/Nursing ServicesHealth Services Operates a charity which focuses on the early diagnosis of pancreatic cancer | Health Services |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of genomic drugs | Commercial Services |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Health Technology |
Surrozen, Inc.
 Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a drug discovery biotechnology company | Commercial Services |
- Stock Market
- Insiders
- Anna Berkenblit
